Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 601 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: E=Placebo Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

S0000 Selenium and Vitamin E in Preventing Prostate Cancer

NCT00006392
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vitamin E, Selenium, Vitamin E placebo, selenium placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
50 Years to 120 Years · Male only
Enrollment
35,533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
13
States / cities
Chicago, Illinois • Joliet, Illinois • Maywood, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Misoprostol Versus Dilapan-S for Cervical Preparation

NCT00835731
View directory record Official record
Conditions
Cervical Ripening
Interventions
misoprostol, Dilapan-S, vitamin B-12
Drug · Device
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study of HP802-247 in Venous Leg Ulcers

NCT00852995
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Stasis Ulcers
Interventions
HP802-247, Placebo (Vehicle)
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
29
States / cities
Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch

NCT01067781
View directory record Official record
Conditions
Diarrhea
Interventions
Heat-Labile Enterotoxin of E. coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
5
States / cities
Anaheim, California • South Miami, Florida • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement

NCT00756236
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Metoprolol, Esmolol, P-Group
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Results available

Lipopolysaccharide (LPS) Challenge in Depression

NCT03142919
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lipopolysaccharide, Placebo
Biological
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Influencer E-Cigarette and Cannabis Marketing: a Survey-Based Experiment Among Adolescents

NCT06919263
View directory record Official record
Conditions
Electronic Nicotine Delivery Systems
Interventions
Influencer marketing
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
16 Years to 17 Years
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)

NCT00194922
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
E. Coli Strain M17 Probiotic
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2008 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

NCT03471871
View directory record Official record
Conditions
Obstructive Sleep Apnea, Healthy Subjects
Interventions
Placebo, Lemborexant 10 mg, Lemborexant 25 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
11
States / cities
Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, JNJ-95475939, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

NCT05900531
View directory record Official record
Conditions
Obesity
Interventions
K-757, K-757 and open-label sitagliptin, Matching placebo to K-757, Matching placebo to K-757 and matching placebo to K-833, K-757 and K-833, Matching placebo to K-757, open-label sitagliptin
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NCT03682601
View directory record Official record
Conditions
Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
Drug
Lead sponsor
GTO Pharmaceutical, LLC
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

NCT00449982
View directory record Official record
Conditions
Condylomata Acuminata
Interventions
Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
Drug
Lead sponsor
MediGene
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
Davis, San Diego, California • Denver, Colorado • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2007 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

NCT00666562
View directory record Official record
Conditions
Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
Interventions
Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Therapeutic Conventional Surgery
Dietary Supplement · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03963895
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB002 Dose 1, AB002 Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery

NCT02689258
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB019602, Placebo, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal

NCT01872910
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, LY3023703, Celecoxib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety and PK Study of IV TP-271

NCT03234738
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 20, 2026, 8:23 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

NCT07867340
View directory record Official record
Conditions
C-Reactive Protein
Interventions
LY5625573, Midazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Alamitos, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Results available

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

NCT02092961
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Glendale, Arizona • Paradise Valley, Arizona • Phoenix, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 20, 2026, 8:23 AM EDT